FIELD: medicine.
SUBSTANCE: invention relates to an enhancer of memory T- or B-cells in the body of an administered subject, the said enhancer being an inhibitor of cancer recurrence, and an inducer for inducing memory function of T- or B-cells in the body. The following is proposed: the use of a T-cell that contains a nucleic acid encoding IL-7 and a nucleic acid encoding the chemokine CCL19, expressing IL-7 and CCL19, and having a cell surface molecule (CAR or TCR), or a pharmaceutical composition consisting of the said T-cell and a pharmaceutically acceptable additive as a cancer recurrence inhibitor attributed to a cancer cell lacking an antigen that is specifically recognized by the said cell surface molecule.
EFFECT: invention makes it possible to induce memory function in endogenous T- or B-cells in order to continue rejection of a malignant tumor for a long period of time.
3 cl, 19 dwg, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CAR EXPRESSION VECTOR AND CAR-EXPRESSING T CELLS | 2015 |
|
RU2670147C1 |
| METHODS OF EXPANSION OF ANTIGEN-SPECIFIC CAR-T-CELLS, COMPOSITIONS AND THEIR USE | 2019 |
|
RU2800920C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2770002C2 |
| T-CELL COMPOSITIONS WITH T-CELL RECEPTOR DEFICIENCY | 2013 |
|
RU2781979C2 |
| CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) FOR CANCER TREATMENT | 2019 |
|
RU2811466C2 |
| THERAPY METHODS BASED ON CAR T-CELLS WITH INCREASED EFFICIENCY | 2016 |
|
RU2788131C2 |
| PRODUCTION OF CONSTRUCTED CELLS FOR ADOPTIVE CELL THERAPY | 2017 |
|
RU2780156C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED B-CELL MATURATION ANTIGEN | 2013 |
|
RU2766608C2 |
| IMPROVED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | 2021 |
|
RU2820497C1 |
